| Name | Bioventix |
|---|---|
| Epic | BVXP |
| Isin | GB00B4QVDF07 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 3,200.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £167.03 | Debt ratio | n/a |
| Shares in issue | 5.22 | Debt-to-equity ratio | n/a |
| P/E ratio | 28.4 | Assets / equity ratio | n/a |
| Total dividends per share | 155.00p | Price to book value | n/a |
| Dividend yield | 3.5 | ROCE | n/a |
| Dividend cover | 1 | EPS growth | -3 |
| Earning per share | 155.12 | 52-week high / low | 3,110.00p / 5,060.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| 2nd Interim | 2024-11-07 | 2024-11-21 | 87.00p |
| 1st Interim | 2024-04-11 | 2024-04-26 | 68.00p |
| 2nd Interim | 2023-11-09 | 2023-11-24 | 90.00p |
| 1st Interim | 2023-04-06 | 2023-04-21 | 62.00p |
| Special | 2022-11-03 | 2022-11-18 | 26.00p |
| 2nd Interim | 2022-11-03 | 2022-11-18 | 74.00p |
| 1st Interim | 2022-04-07 | 2022-04-22 | 52.00p |
| Special | 2021-10-28 | 2021-11-12 | 38.00p |
| 2nd Interim | 2021-10-28 | 2021-11-12 | 62.00p |
| Company name | Bioventix |
|---|---|
| Address | 27-28 Eastcastle Street, London, United Kingdom, W1W 8DH |
| Telephone | |
| Website | http://www.bioventix.com |
| Director | Position |
|---|---|
| Mr Peter John Harrison | CEO |
| Mr Bruce Hiscock | CFO |
| Mr Ian James Nicholson | Chairman |
| Mr Nicholas (Nick) John McCooke | Independent Non-Executive Director |
| Mr Joanne (Jo) Pisani | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 30/06/24 | 30/06/23 | 30/06/22 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | 0.43 | 0.61 | 0.61 |
| Total non-current assets | 0.9 | 1.19 | 1.3 |
| Inventory / work in progress | 0.62 | 0.57 | 0.46 |
| Trade and other receivables | 6.21 | 5.81 | 5.22 |
| Cash and equivalents | 6 | 5.72 | 6.13 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 13.73 | 13.28 | 13.12 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 1.73 | 1.2 | 1.25 |
| Long term liabilities | 0.02 | 0.02 | 0.04 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.75 | 1.22 | 1.3 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 12 | 12.06 | 11.82 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.26 | 0.26 | 0.26 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 10.27 | 10.33 | 10.23 |
| Share premium account | 1.47 | 1.47 | 1.33 |
| Total equity | 12 | 12.06 | 11.82 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 10.58 | 10.03 | 9.27 |
| Pre-tax profit | 10.6 | 10.13 | 9.28 |